. 2020 Jan 15;111(2):739–748. doi: 10.1111/cas.14268

Table 2.

Outcomes of nine patients with multiple pancreatic ductal adenocarcinomas

Patient ID	Postulated pathogenesis	UICC 8th			First distant metastatic organ	Distant recurrence time^d (months)	Status	Survival time^d (months)
Patient ID	Postulated pathogenesis	T	N	Stage	First distant metastatic organ	Distant recurrence time^d (months)	Status	Survival time^d (months)
MPKO01	Multicentric carcinogenesis	2/1	1	IIB^a	NA^c	NA^c	NED	53
MPKO02	Multicentric carcinogenesis	2/1	1	IIB^a	Lung	18	AWD	48
MPKO03	Multicentric carcinogenesis	2 3	0 1	IB^b IIB^b	Lung, bone, peritonea	9	DOD	20
MPKO04	Multicentric carcinogenesis	2/1 2	1 1	IIB^a^,^b IIB^b	NA^c	NA^c	DOO	50
MPKO05	Intrapancreatic metastasis	2 2/1	1 0	IIB^b IB^b	Lymph node	11	DOD	18
MPKO06	Intrapancreatic metastasis	1c	1	IIB	Lung	11	DOD	44
MPKO07	Intrapancreatic metastasis	2	2	III	Liver	7	DOD	27
MPKO08	Intrapancreatic metastasis	2	2	III	Liver	16	DOD	35
MPKO09	Intrapancreatic metastasis	2	2	III	Liver	6	DOD	15

Abbreviation: AWD, alive with disease; DOD, died of disease; DOO, died of other causes; NA, not applicable; NED, no evidence of disease.

Stages for synchronous multicentric tumors were defined by the worst T factors and the N factors.

Stages for metachronous tumors were assigned to each timing.

Not applicable because there was no recurrence (MPKO01) or distant metastasis (MPKO04).

Survival time was defined as the period from the date of surgery that showed multiple pancreatic cancers to event (death or recurrence) or to the end of follow up.